Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-06-17
2008-06-17
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S326000, C530S327000, C514S015800
Reexamination Certificate
active
07387998
ABSTRACT:
The invention describes methods for inhibiting angiogenesis in a tissue by administering an antagonist that specifically binds to a proteolyzed or denatured laminin with substantially greater affinity than to the native form of laminin. Methods utilizing such antagonists for therapeutic treatment of tumor growth, tumor metastasis or of restenosis also are described, as are methods to use such antagonists as diagnostic markers of angiogenesis in normal or diseased tissues both in vivo and ex vivo.
REFERENCES:
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5112946 (1992-05-01), Maione
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202352 (1993-04-01), Okada et al.
patent: 6071520 (2000-06-01), Noteborn et al.
patent: 7122635 (2006-10-01), Brooks et al.
patent: 2004/0224896 (2004-11-01), Brooks
patent: WO 00/40597 (2000-07-01), None
patent: WO-00-59532 (2000-10-01), None
Amstutz, et al., In vitro display technologies: novel developments and applications. Current Opinion in Biotechnology 2001;12:400-405.
Blood, et al., Biochim. Biophys. Acta. 1990;1032:89-118.
Brooks, et al., J Clin. Invest. 1995;96:1815-1822.
Brooks, et al., Cell 1994;79:1157-1164.
Brooks, et al., Cell 1998;92:391-400.
Green, et al., Proc. Natl. Acad. Sci. USA 2003;100:1010-1015.
Guo, et al., In vitro evolution of amphioxus insulin-like peptide to mammalian insulin. Biochemistry 2002;41:10603-10607.
Hangai, et al., Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. American Journal of Pathology 2002;161(4):1429-1437.
Heeley RP, Endocr. Res. 2002;28:217-229.
Kurschat, et al., Clin. Exp. Dermatol. 2000;25:482-489.
Liljeblad, et al., Analysis of agalacto-IgG in rheumatoid arthritis using surface plasmon resonance. Glycoconjugate Journal 2000;17:323-329.
Liotta, et al., Cell 1991;64:327-336.
Roskelly, et al., Curr. Op. Cell Biol. 1995;7:736-747.
Stephanopoulos G, Metabolic engineering by genome shuffling. Nature Biotechnology 2002;20(7):666-668.
Tani, et al., In vitro selection o fibronectin gain-of-function mutations. Biochem. J. 2002;365:287-294.
Varner, et al., Cell Adh. Commun. 1995;3:367-374.
Xu, et al., Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma 2000;19(5)375-385.
Xu, et al., Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. Journal of Cell Biology 2001;154(5):1069-1079.
Weidner, et al., J. Natl. Cancer Inst. 1992;84:1875-1887.
Weidner, et al., N. Engl. J Med. 1991;324:1-7.
Wyckoff, et al., Cancer Res. 2000;60:2504-2511.
Akalu , A. et al., “Inhibition of angiogenesis and tumor metastasis by targeting a matrix immobilized cryptic extracellular matrix epitope in laminin,” Cancer Res. 67(9):4353-4363 (2007).
Gonzalez, A. et al., “Complex interactions between the laminin alpha 4 subunit and integrins egulate endothelial cell behavior in vitro and angiogenesis in vivo,” PNAS USA 99(25):16075-16080 (2002).
Kikkawa, Y. et al., “Isolation and characterization of laminin-10/11 secreted by human lung carcinoma cells. Laminin-10/11 mediates cell adhesion through integrin alpha3 beta1,” J. Biol. Chem. (online), Am. Soc. Biochem. Mol. Biol., 273 (25):15854-15859 (1998).
Kurkinen, M. et al., “In vitro synthesis of laminin and entactin polypeptides,” J. Biol. Chem. 258(10):6543-6548 (1983).
EP04758409.9 Supp EP Search Report dated Jul. 19, 2007.
Akalu Abebe
Brooks Peter C.
Heard Thomas S
New York University
Tsang Cecilia
Wilson Sonsini Goodrich & Rosati
LandOfFree
STQ peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with STQ peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and STQ peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2802257